Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lovastatin for hypercholesterolemia.

F P Zeller1, K C Uvodich

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago 60612.

Drug Intelligence & Clinical Pharmacy
|July 1, 1988
PubMed
Summary

Lovastatin, a cholesterol-lowering drug, effectively reduces total and LDL cholesterol by 25-30%. While generally safe, potential side effects include gastrointestinal issues and elevated liver enzymes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alteplase: a tissue plasminogen activator for acute myocardial infarction.

Drug intelligence & clinical pharmacy·1988
Same author

Tolerance to organic nitrates in ischemic heart disease.

Drug intelligence & clinical pharmacy·1987
Same author

Controversies in the use of transdermal nitroglycerin systems.

Clinical pharmacy·1987
Same author

Fish oil: effectiveness as a dietary supplement in the prevention of heart disease.

Drug intelligence & clinical pharmacy·1987
Same author

Bepridil: a new long-acting calcium channel blocking agent.

Drug intelligence & clinical pharmacy·1987
Same author

The use of intravenous dipyridamole in thallium 201 myocardial perfusion imaging.

Pharmacotherapy·1987

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Lovastatin is the first approved HMG-CoA reductase inhibitor for primary hypercholesterolemia.
  • It serves as an adjunctive therapy to diet, with initial dosing at 20 mg/day.

Purpose of the Study:

  • To evaluate the efficacy and safety of lovastatin in treating hypercholesterolemia.
  • To review pharmacokinetic properties and clinical trial data.

Main Methods:

  • Clinical trials comparing lovastatin to placebo and other lipid-lowering drugs.
  • Analysis of pharmacokinetic data including absorption, protein binding, and elimination pathways.

Main Results:

  • Lovastatin lowers total cholesterol and LDL cholesterol by 25-30%, with better response in nonfamilial hypercholesterolemia.
  • Adverse effects are infrequent, with common complaints of flatulence and diarrhea; rare severe effects include elevated liver enzymes.

Conclusions:

  • Lovastatin demonstrates good efficacy and a low incidence of side effects for hypercholesterolemia management.
  • Long-term safety data and competition will shape its future therapeutic role.

Related Experiment Videos